Investors & Media

Investor FAQs

 

SAGE Therapeutics is headquartered at 215 First Street, Cambridge, MA 02142. The main phone number is 617-299-8380.

SAGE was incorporated in 2010 in the state of Delaware.

SAGE Therapeutics is traded on the NASDAQ Global Market under the ticker symbol SAGE and its CUSIP number is 78667J 108.

SAGE Therapeutics’ initial public offering (IPO) occurred on July 18, 2014

December 31st.

Computershare
P.O. Box 505000
Louisville, KY 40233
http://www-us.computershare.com/contactus/

SAGE Therapeutics does not have a direct stock purchase plan. Shares can be purchased through a stockbroker of your choice.

PricewaterhouseCoopers LLP
101 Seaport Boulevard, Suite 500
Boston, MA 02110
(617) 530-5000

The SAGE Therapeutics press release archives can be accessed at http://investor.sagerx.com/releases.cfm

The SAGE Therapeutics SEC filings can be accessed at http://investor.sagerx.com/sec.cfm or www.sec.gov.

You can submit queries to SAGE Therapeutics’ investor relations department by contacting ir@sagerx.com or 617-299-8380.